108 related articles for article (PubMed ID: 23506303)
1. Risedronate-loaded Eudragit S100 microparticles formulated into tablets.
Velasquez AA; Mattiazzi J; Ferreira LM; Pohlmann L; Silva CB; Rolim CM; Cruz L
Pharm Dev Technol; 2014 May; 19(3):263-8. PubMed ID: 23506303
[TBL] [Abstract][Full Text] [Related]
2. Novel Pullulan-Eudragit® S100 blend microparticles for oral delivery of risedronate: formulation, in vitro evaluation and tableting of blend microparticles.
de Arce Velasquez A; Ferreira LM; Stangarlin MF; da Silva Cde B; Rolim CM; Cruz L
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():212-7. PubMed ID: 24656371
[TBL] [Abstract][Full Text] [Related]
3. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
[TBL] [Abstract][Full Text] [Related]
4. Eudragit-S, Eudragit-L and cellulose acetate phthalate coated polysaccharide tablets for colonic targeted delivery of azathioprine.
Kotagale N; Maniyar M; Somvanshi S; Umekar M; Patel CJ
Pharm Dev Technol; 2010; 15(4):431-7. PubMed ID: 20236031
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Ceolus™ microcrystalline cellulose grades for the direct compression of enteric-coated pellets.
Kucera SU; DiNunzio JC; Kaneko N; McGinity JW
Drug Dev Ind Pharm; 2012 Mar; 38(3):341-50. PubMed ID: 21870908
[TBL] [Abstract][Full Text] [Related]
6. Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets.
Bendas ER; Christensen JM; Ayres JW
Drug Dev Ind Pharm; 2010 Apr; 36(4):393-404. PubMed ID: 19740039
[TBL] [Abstract][Full Text] [Related]
7. Suitability of κ-carrageenan pellets for the formulation of multiparticulate tablets with modified release.
Ghanam D; Kleinebudde P
Int J Pharm; 2011 May; 409(1-2):9-18. PubMed ID: 21335073
[TBL] [Abstract][Full Text] [Related]
8. Physicomechanical properties of naproxen-loaded microparticles prepared from Eudragit l100.
Maghsoodi M
AAPS PharmSciTech; 2009; 10(1):120-8. PubMed ID: 19184624
[TBL] [Abstract][Full Text] [Related]
9. Cationic Eudragit® polymers as excipients for microparticles prepared by solvent evaporation method.
Vysloužil J; Bavoľárová J; Kejdušová M; Vetchý D; Dvořáčková K
Ceska Slov Farm; 2013 Dec; 62(6):249-54. PubMed ID: 24393112
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
11. Tablets compressed with gastric floating pellets coated with acrylic resin for gastro retention and sustained release of famotidine: in-vitro and in-vivo study.
Qi X; Jiang Y; Zhang H; Wu Z
J Pharm Pharmacol; 2015 Apr; 67(4):493-500. PubMed ID: 25495700
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the dissolution characteristics of capsule and tablet dosage forms of melt granulations of paracetamol--diluent effects.
Uhumwangho MU; Okor RS
Acta Pol Pharm; 2007; 64(1):73-9. PubMed ID: 17665854
[TBL] [Abstract][Full Text] [Related]
13. Continuous direct tablet compression: effects of impeller rotation rate, total feed rate and drug content on the tablet properties and drug release.
Järvinen MA; Paaso J; Paavola M; Leiviskä K; Juuti M; Muzzio F; Järvinen K
Drug Dev Ind Pharm; 2013 Nov; 39(11):1802-8. PubMed ID: 23163644
[TBL] [Abstract][Full Text] [Related]
14. Development of HPMC and Eudragit S100 blended microparticles containing sodium pantoprazole.
Raffin RP; Colomé LM; Haas SE; Jornada DS; Pohlmann AR; Guterres SS
Pharmazie; 2007 May; 62(5):361-4. PubMed ID: 17557744
[TBL] [Abstract][Full Text] [Related]
15. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
Ghorab DM; Amin MM; Khowessah OM; Tadros MI
Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
[TBL] [Abstract][Full Text] [Related]
16. Eudragit S100 coated microsponges for Colon targeting of prednisolone.
Kumari A; Jain A; Hurkat P; Tiwari A; Jain SK
Drug Dev Ind Pharm; 2018 Jun; 44(6):902-913. PubMed ID: 29260916
[TBL] [Abstract][Full Text] [Related]
17. Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets.
Lin SY; Lin KH; Li MJ
J Pharm Sci; 2002 Sep; 91(9):2040-6. PubMed ID: 12210050
[TBL] [Abstract][Full Text] [Related]
18. Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system.
Kumar RV; Sinha VR
Acta Pharm; 2011 Sep; 61(3):343-51. PubMed ID: 21945913
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers.
Simanjuntak R; Setiawati E; Yunaidi DA; Handayani LR; Setiawati A; Utami BS; Rosa TA; Sholeh AB
Drug Res (Stuttg); 2014 Mar; 64(3):136-40. PubMed ID: 24002927
[TBL] [Abstract][Full Text] [Related]
20. Preparation and in vivo evaluation of spray dried matrix type controlled-release microparticles of tamsulosin hydrochloride for orally disintegrating tablet.
Park CW; Kim JY; Rhee YS; Oh TO; Ha JM; Park ES
Drug Dev Ind Pharm; 2012 Oct; 38(10):1179-87. PubMed ID: 22200122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
